Navigation Links
Dips in Breast Cancer Rates Seen Most in Affluent Women
Date:2/19/2010

Finding suggests that drops in HRT use explain the trend, researchers say

FRIDAY, Feb. 19 (HealthDay News) -- Breast cancer rates are declining, especially among women over 50 who have estrogen receptor-positive tumors, and now a new study narrows down the reason why.

After analyzing data on more than 350,000 women with breast cancer, Harvard researchers concluded that the decline may be linked with decreasing use of hormone replacement therapy -- and that association, in turn, may explain why the decline is especially evident among white, affluent women.

Those are the very women most likely to have used hormone replacement therapy, experts said, and to have stopped using it following the July 2002 release of the results of the Women's Health Initiative, a large national study that discovered an increased risk of breast cancer and heart disease with hormone replacement therapy.

The new study lends credence to the speculation about what's behind the decline. "Our study provides evidence to support the idea that the observed declines are due to the changing use of hormone therapy, by showing that the declines in breast cancer rates were sharpest among those women most likely to have received hormone therapy -- that is, affluent white women," said study co-author Jarvis Chen, a research scientist at the Harvard School of Public Health.

The new study was released online Feb. 10 and will be published in the April supplement of the American Journal of Public Health.

"We further showed that declines in breast cancer rates vary within racial/ethnic groups by socioeconomic position, and that the declines primarily affect rates of estrogen receptor-positive cancers," Chen said.

Lead study author Nancy Krieger, a professor in the department of society, human development and health at the Harvard School of Public Health, and her colleagues analyzed breast cancer data from the U.S. Surveillance, Epidemiology and End Result (SEER) database, stratified by race/ethnicity, county income level, age and estrogen receptor status of the tumor. The women had been diagnosed between 1992 and 2005.

The SEER database does not include individual socioeconomic information, Chen said. "To overcome this, we analyzed breast cancer rates in relation to the socioeconomic characteristics of the counties where the women lived," she explained.

"The recent decline in U.S. breast cancer incidence was not equally beneficial to all women, but instead mirrored the social patterning of hormone therapy use," the researchers concluded.

The silver lining? The fact that minorities and low-income women used hormone therapy less -- because of expense and less access to health care -- may have spared them from increases in breast cancer diagnoses, Chen said.

The new findings come as no surprise to Susan Brown, director of health education for Susan G. Komen for the Cure.

"We know there are ethnic differences in breast cancer incidence," she said. "African-American women are more likely to get breast cancer at an earlier age, and they are more likely to be diagnosed with breast cancer tumors that have molecular markers associated with a poorer prognosis."

ER-negative tumors, she said, are also more common in black women, and experts would not expect the rates of those tumors to be affected by discontinuing HRT use.

Brown brings up another factor that could be contributing to the trend: the declining rate of mammography screening. "We are hoping we aren't seeing a decline in incidence due to mammography screening rates being down," she said.

More information

To learn more about menopausal hormone therapy use, visit the U.S. National Institutes of Health.



SOURCES: Susan Brown, director, health education, Susan G. Komen for the Cure, Dallas; Jarvis Chen, Sc.D., research scientist, Harvard School of Public Health, Boston; Feb. 10, 2010, American Journal of Public Health, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Aspirin May Boost Breast Cancer Survival
2. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
3. Study reveals genetic link between mammographic density and breast cancer
4. Cancer publishes study confirming disparity in breast cancer treatment
5. PA Breast Cancer Coalition Launches Income Tax Refund Campaign
6. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
7. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
8. MRI May Not Add Value to Routine Breast Cancer Care
9. MSU researcher linking breast cancer patients with alternative therapies
10. Hormone May Prevent Aggressive Breast Cancer
11. Few Women at High Risk for Breast Cancer Take Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... provide first-quality education and high-level training standards to an international multidisciplinary group of ... disorder problems. As a way to further its mission at the grassroots level, ...
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... San ... of iTero Element, the latest in 3-D scanning device which is capable of taking ... the latest advances in dentistry, such as CAD CAM restorations , in terms ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond ... strives to better communities around the world by offering the Gensuite team and ... opportunity for team members to become involved in a cause that is bigger ...
(Date:1/15/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... services. Albertsons Companies is the largest national food and drug chain with ... Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to meeting national standards ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... CRUZ, Calif. , Jan. 16, 2017  Dovetail ... Dovetail™ Hi-C sequencing and assembly service, which yields chromosome-scale ... be presented in a Dovetail-hosted workshop on Jan. 17 ... in San Diego . ... services with the launch of our Dovetail Hi-C offering," ...
(Date:1/16/2017)... 2017  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased ... , CFA to its Board of Directors. He is ... Asset Management LLC . He is also the Chief ... investment advisory firm with over $1.5 billion under management. ... in security analysis and portfolio management. He began his ...
(Date:1/15/2017)... DUBLIN , January 16, 2017 ... produits innovants à base de collagène pour la régénération de ... au poste de directeur général avec effet immédiat. ... Bill est ... qui a occupé plusieurs postes de gestion générale et de ...
Breaking Medicine Technology: